Table 4.

Summary of adverse events occurring in ≥10% of patients across cohorts, by organ and severity (n = 30)

AEs, n (%)Any gradeGrade 3–4
Blood and lymphatic system disorders
 Anemia15 (50.0)5 (16.7)
 Lymphopenia12 (40.0)11 (36.7)
 Neutropenia9 (30.0)9 (30.0)
 Thrombocytopenia11 (36.7)7 (23.3)
Gastrointestinal disorders
 Diarrhea6 (20.0)2 (6.7)
 Nausea20 (66.7)1 (3.3)
 Vomiting16 (53.3)2 (6.7)
General disorders and administration site conditions
 Asthenia14 (46.7)0
 Edema limbs3 (10.0)1 (3.3)
 Fever8 (26.7)2 (6.7)
Infections and infestations
 Bronchitis6 (20.0)1 (3.3)
 Urinary infection3 (10.0)1 (3.3)
 Weight loss4 (13.3)0
Musculoskeletal disorders: Bone pain3 (10.0)1 (3.3)
Renal and urinary disorders: Acute renal failure4 (13.3)3 (10.0)
Respiratory, thoracic, and mediastinal disorders
 Cough4 (13.3)1 (3.3)
 Dyspnea4 (13.3)3 (10.0)
Vascular disorders: Hypertension6 (20.0)5 (16.7)
Neurologic toxicities: Sensitive neuropathy10 (33.3)0